Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed a significant expansion of its spider silk production capacity. The company has constructed a new production center that increases its rearing capacity by more than eight times its current operations. This expansion is part of a strategic investment plan to rapidly scale production, following successful spring production trials.
The new facility features dedicated spaces for each BAM-1 parental line and a BAM-1 hybrid hatchery. It is expected to meet spider silk production needs through 2025. The company is now transitioning operations to this new space and finalizing backup power systems. The first production cycle in this facility, set to begin later this month, will be the largest single-cycle rearing of BAM-1 parental strains in the company's history.
Kraig Biocraft Laboratories (OTCQB: KBLB) has significantly improved its spider silk production efficiency. Under the guidance of Dr. Nirmal Kumar, the company has implemented new silk cocoon reeling protocols, resulting in nearly doubled reeling efficiency compared to previous production runs. This improvement addresses one of Kraig's top three goals for increasing production.
The company recently harvested its third production cycle of proprietary BAM-1 hybrid cocoons, which have been processed using the enhanced protocols. Kraig Labs is now focusing on increasing individual cocoon size and overall production volumes. The team has also selected top-performing BAM-1 parent line cocoons for production expansion this fall.
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully completed its third commercial spider silk production cycle, focusing on BAM-1 recombinant spider silk hybrids. This marks the second successful commercial production of their most advanced spider silk hybrids. The company chose to operate during the rainy season to challenge test the robustness of BAM-1 hybrids and optimize their silkworm colony.
Dr. Nirmal Kumar, a sericulture expert, is analyzing data to guide future production. Over the next two weeks, Kraig Labs will harvest cocoons and send them to local reeling facilities to refine operations and produce additional spider silk for market use. COO Jon Rice emphasized the hybrids' resilience and their role as a catalyst for scalable, commercially sustainable spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB) has confirmed that its commercially produced recombinant spider silk matches the exceptional strength and toughness of previous small batch testing. This breakthrough opens doors for aggressive commercial production. Recent tests at the company's R&D headquarters compared samples of Kraig's spider silk against mundane silk using a high-precision tensile testing machine. The results verified the mechanical superiority of Kraig's spider silk, with no loss in strength or toughness despite the significant increase in production scale.
COO Jon Rice stated that this confirmation unlocks a scalable system for commercial sustainable spider silk production. The company is now confident to proceed with its spider silk production scale-up, potentially revolutionizing the global textile industry.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces the return of renowned sericulture expert Dr. Nirmal Kumar to oversee the completion of the second production cycle of BAM-1 spider silk hybrids. This cycle builds on the success of the first production completed in July 2024. Dr. Kumar will supervise cocoon production, monitor quality, and lead large-scale selective matings for a planned 10X capacity increase. The company aims to produce metric-ton level spider silk and solidify its position in cost-effective, eco-responsible spider silk production. CEO Kim Thompson states that 2024 is a breakout year for Kraig Labs, with ongoing expansion of BAM-1 production hybrids.
Kraig Biocraft Laboratories (OTCQB: KBLB) has entered the rapid growth rearing phase for its third spider silk production cycle of the season. The company has expanded production space to accommodate the rapidly growing silkworms, which are preparing to spin proprietary recombinant spider silk cocoons. The BAM-1 Hybrids are reported to be the most robust production strain ever fielded by the company.
Kraig Labs has implemented a batch-rearing process to optimize silkworm colony health and ensure ideal rearing conditions. This approach aims to minimize overcrowding and manage mulberry supply during the rainy season. The company's COO, Jon Rice, highlighted significant breakthroughs in their business plan, emphasizing advancements in production capacities for cost-effective, commercially scalable spider silk.
Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its third and largest production cycle of spider silk for 2024. This expanded cycle, released in scheduled batches, aims to address the rainy season peak while driving towards 2024 production volume goals. The company has brought an additional production facility online to support increased silkworm rearing and silk production.
Kraig Labs expects to add more facilities over the next two months, supporting its goal of delivering the first metric ton of spider silk to global markets. Each production cycle further validates the company's spider silk production model and demonstrates its specialized silkworms' readiness for mass production. The company's CEO, Kim Thompson, described 2024 as an inflection point for spider silk commercialization.
Kraig Biocraft Laboratories (OTCQB: KBLB) has completed phase one of its spider silk production facility expansion on budget and on schedule. The expanded facility will support the company's third production wave starting this month, allowing for continued production during the rainy season. Key points include:
- New space for processing, drying, and storing fresh mulberry
- Ongoing construction of a larger silkworm egg hatchery
- Hatchery expected to address production needs for 12-18 months
- Part of systematic growth plan for commercial-scale spider silk production
CEO Kim Thompson emphasized these investments will help bring cost-effective and eco-responsible spider silk to global markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) has announced a new production agreement for its recombinant spider silk technology. This agreement aims to enhance the company's production capabilities by collaborating with existing silk manufacturers to adapt their facilities to produce Kraig Labs’ proprietary spider silk. The deal underscores the company's ongoing efforts to commercialize spider silk production, following the rollout of new production hybrids earlier this year. CEO Kim Thompson highlighted the company's commitment to expanding its production footprint and capacity, emphasizing the potential of commercial-scale spider silk. For more details, visit Kraig Labs' website.
Kraig Biocraft Laboratories (OTCQB: KBLB) has reached full capacity at its current production site, fulfilling its expansion goals for early 2024. The company is advancing with plans for additional production facilities. This expansion, initiated after observing strong growth in new spider silk hybrids, will occur in two phases. The first phase, addressing near-term capacity needs, is set for completion within weeks. The larger second phase, which will provide hatchery space for the next 12-18 months, will conclude by early fall. Permitting has been approved, and construction is underway. CEO Kim Thompson emphasized the company's commitment to achieving ambitious spider silk production targets in 2024. The expansion aligns with Kraig Labs' vision for cost-effective, commercial-scale spider silk production. The third wave of recombinant spider silk production will begin this month, focusing on scaling up output.
FAQ
What is the current stock price of Kraig Biocraft Laboratories In (KBLB)?
What is the market cap of Kraig Biocraft Laboratories In (KBLB)?
